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Abstract
CTCF is a ubiquitous epigenetic regulator that has been proposed as a master keeper of chromatin organisation. CTCF-like,
or BORIS, is thought to antagonise CTCF and has been found in normal testis, ovary and a large variety of tumour cells. The
cellular function of BORIS remains intriguing although it might be involved in developmental reprogramming of gene
expression patterns. We here unravel the expression of CTCF and BORIS proteins throughout human epidermis. While CTCF
is widely distributed within the nucleus, BORIS is confined to the nucleolus and other euchromatin domains. Nascent RNA
experiments in primary keratinocytes revealed that endogenous BORIS is present in active transcription sites. Interestingly,
BORIS also localises to interphase centrosomes suggesting a role in the cell cycle. Blocking the cell cycle at S phase or
mitosis, or causing DNA damage, produced a striking accumulation of BORIS. Consistently, ectopic expression of wild type
or GFP- BORIS provoked a higher rate of S phase cells as well as genomic instability by mitosis failure. Furthermore, down-
regulation of endogenous BORIS by specific shRNAs inhibited both RNA transcription and cell cycle progression. The results
altogether suggest a role for BORIS in coordinating S phase events with mitosis.
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Introduction
CTCF is a Zinc finger DNA binding protein initially identified
as a transcriptional regulator [1] and later established as a
chromatin insulator binding protein [2]. CTCF has attracted
much attention in the last years since it has been associated with
heritable genomic imprinting [2,3] and it has been proposed as a
master keeper of global chromatin structure [4,5]. The essential
role for CTCF in genome regulation was revealed by genome-
wide analysis [6,7,8,9].
CTCF-like protein BORIS (Brother of the Regulator of
Imprinted Sites; or CTCFL) has been proposed to be a CTCF
antagonist [10]. The BORIS protein (663 aminoacids) exhibits
high homology with CTCF in the central domain containing 11
Zinc-Finger elements, where every amino acid relevant to DNA
binding is exactly the same. CTCF and BORIS might thus bind to
the same DNA target sequences. On the contrary, the flanking N-
and C- terminal regions show very little sequence homology
between of BORIS and CTCF, implying that they may recruit
different associated cofactors [11,12,13].
BORIS was originally found only in spermatocytes within
normal tissues [11]. More recently, it has been detected in human
oocytes, ovary, embryonic stem cells [14] and various foetal tissues
[15]. Consistent with its significant level of expression in testis,
BORIS knock-out mice suffer from spermatogenesis defects that
result in small testes [16]. In addition, BORIS is aberrantly
expressed in many tumours [17,18,19] and was thus defined
within the cancer-testis group of genes [10]. Because of the high
homology of the zinc fingers domain, BORIS is thought to bind to
the same DNA sequences as CTCF [10]. However, CTCF and
BORIS differ significantly in their amino and carboxy termini,
suggesting that they may act differently by recruitment of different
associated cofactors [11,13]. They are thought to be antagonists
also because of the mutually exclusive manner of their distribution
during male germ cell development, although they are aberrantly
co-expressed in cancer cells. CTCF has been considered as a
tumour suppressor (reviewed in [20], it inhibits cell growth when
ectopically expressed [10,21,22], it is ubiquitously distributed in
somatic cells and it is altered in a number of tumours through
genetic and epigenetic mechanisms [23,24]. It is unclear whether
aberrant expression of BORIS interferes in tumour cells with the
normal function of CTCF [10], or it elicits CTCF independent
functions.
The regulation of BORIS is a complex promoter- and cell type-
dependent process [25]. 23 differentially expressed isoforms of
BORIS have recently been reported [15]. Although the biological
data available have suggested a role for BORIS in epigenetic
genome reprogramming in testis [11] and in the proliferation of
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cancer cells [17], little is known about the mechanisms eliciting
these functions. In part this issue has been hampered by the
restricted detection of the BORIS protein in normal tissues. In
order to gain insight into this issue we have studied a primary
human system. After running a small scale screening on a panel of
cell lines and tissues, we detected BORIS mRNA in skin samples.
The epidermis is a stratified epithelium that self-renews
throughout adult life from the stem cells in the basal layer [26].
As keratinocytes differentiate terminally, they cease proliferation
and migrate through the suprabasal layers. During this process
keratinocytes evolve from quiescent stem cells to actively
proliferating cells and subsequently, to actively metabolic differ-
entiating cells. Keratinocyte differentiation involves a significant
cell mass increase and high production of RNA and proteins
[27,28] and requires continuous reprogramming of gene expres-
sion and chromatin remodelling [29].
We have explored the distribution of CTCF and BORIS in
human epidermis in situ and in primary keratinocytes in vitro. We
show a striking localisation of BORIS to the nucleolus and other
areas of active transcription and to interphase centrosomes. This
localisation was confirmed in mouse testis and a panel of cell lines
from diverse origins. By ectopic expression or inactivation studies,
we also demonstrate a function of BORIS in RNA transcription,
cell cycle progression and genomic instability. We discuss the
potential implications of this novel function of BORIS for cancer
cells.
Materials and Methods
Skin Biopsies and Cell Culture, Treatments and
Transfections
Ethics Statement: Ethical permission for this study was
demanded, approved and obtained from the Ethical Committee
for Clinical Research of the Cantabria Council, Spain (FIS-08/
0890). In all cases, human tissue material to discard after surgery
was obtained with informed written consent presented by
clinicians to the patients or the parents/guardians of minors
involved in the study, the identity was not kept and the material
was thus treated completely anonymously.
Skin biopsies were provided by the Plastic Surgery and
Paediatrics Services of clinic St Jean (Montpellier, France) and
of Hospital Marque´s de Valdecilla (Santander, Spain) from
circumcisions (neonatal foreskin) or from plastic surgery (adult
breast, scalp). The fat and most of the connective tissue was
removed using curved scissors, and the epidermis was embedded
in OCT compound (Tissue-Tek, Sakura) and submerged in liquid
Nitrogen (Thermo Shandon). Frozen tissue was microsectioned
and 5–10 mm thick sections were collected on Superfrost Plus
glass-slides (Thermo Scientific) and air dried [30].
Primary keratinocytes were isolated from neonatal human
foreskin and cultured in the presence of a mouse fibroblast feeder
layer (inactivated by a 2 h treatment with 4 mg/ml mitomycin C),
10% serum and 1.2 mM Ca+2, as described [31,32].
Primary keratinocytes were treated for 48 hours with cdk
inhibitors or mitosis kinase inhibitors: 50 mM of hydroxyurea
(Tocris Bioscience), 1 mM of the Aurora B Kinase inhibitor
ZM447439 (Tocris Bioscience) or 100 nM of the Polo Like Kinase
inhibitor BI2536 (Axon MedChem BV). Parallel control cultures
were always subjected to the DMSO vehicle.
HEK293T (human embryonic kidney; [33]), HeLa (human
cervical cancer; [34]), HCT116 (human colorectal cancer; [35]),
MCF7 (human breast cancer; [36]), MEF-1 (obtained from the
American Type Culture Collection) and 3T3-J2 (mouse embry-
onic fibroblasts; [31]) cell lines were grown in DMEM supple-
mented with 10% foetal calf serum (FCS; LONZA), 150 mg/ml of
gentamycin and 2 mg/ml of ciprofloxacin at 37uC in a humidified
5% CO2 atmosphere. HEK293T cells were transfected by the use
of the jetPEI transfection reagent (poly Plus) as indicated by the
manufacturer, with the following constructs: pEGFP-CTCF [37],
pCDNA-CTCF [22], pEGFP-BORIS, pCMV-BORIS (kindly
provided by Elena Klenova, University of Essex, UK), pEGFP-
BORIS-ZF-domain (kindly provided by Niels Galjart and Frank
Sleutels, Erasmus MC, Rotterdam, Netherlands), Fibrillarin-
Cherry (kindly gift by Prof. Angus I. Lamond, University of
Dundee, Dundee, UK; [38]) or shRNAs BORIS (Genecopoieia
Inc, MD, USA; see below).
Mice Tissue
Mice in a C57BL/6 background were obtained from Harland
Ibe´rica (Barcelona, Spain) and used to purify RNA from different
tissues for quantitative RT-PCR experiments. All experiments
were performed with 10–12 week-old animals and approved by
the Universidad de Cantabria Institutional Laboratory Animal
Care and Use Committee (Ref. Numb. 2008/07).
RNA Purification and RT-PCR Analysis
Total RNA was extracted from human cell lines and different
mouse and human tissues using Trizol reagent (Invitrogen). 2 mg
of RNA were used for the reverse transcription with the iScript
cDNA Synthesis Kit (Bio-Rad). cDNA was amplified using specific
primers (see Information S1) and Qiagen Quantitect Sybr Green
mix with an iQ5 Real-Time PCR Detection System (Bio-Rad).
Amplification efficiencies, determined by amplifying log dilutions
of plasmids containing the corresponding coding sequences, were
near 100%. For semiquantitative PCR, a Thermal Cycler C1000
(Bio-Rad) was used. The PCR conditions were determined
depending on the nature and complexity of the primers. The
results were normalised to b-actin for human samples and to
GAPDH for mouse samples using the comparative DeltaDeltaCt
(DDCt) method.
Chromatin Immunoprecipitation (ChIP) Assays
ChIP assays were performed using a modified version of the
Upstate Biotechnology protocol. Briefly, 56106 cells were fixed in
1% formaldehyde, lysed in lysis buffer (50 mM Tris-HCl pH 8,
10 mM EDTA, 1% SDS, protease inhibitor cocktail Set I) and
sonicated using a Bioruptor UCD-200 (Diagenode), leading to
fragments between 250 and 1000 bp. ChIP was performed using
Dynabeads-protein G (Invitrogen) coupled to anti-BORIS anti-
body (abcam ab18337) or anti-GFP antibody (Invitrogen A11122).
The DNA recovered was purified (Qiaquick columns, Qiagen) and
analysed by quantitative real time-PCR as described above. PCR
was performed in duplicate with equal amounts of specific
antibody immunoprecipitated sample, control (IgG) and Input.
Primers used for H 42.1 and H 37.9 sites in human ribosomal
DNA and amplification conditions were previously described [39].
Values were normalised to input measurements and enrichment
was calculated using the comparative Ct method.
Immunofluorescence and Confocal Microscopy
For immunofluorescence assays, keratinocytes and adherent cell
lines were grown on glass coverslips. Cells and skin sections were
fixed and permeabilized with cold methanol 220uC) for 10 min,
washed with PBS and successively incubated with primary
antibodies and secondary antibodies. Primary antibodies used
were: anti-CTCF (Abcam ab10571, ab84372 or Upstate 07-729);
anti-BORIS (Rockland 600-401-907; Abcam ab18337 or a
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chicken polyclonal antibody [17]; anti-keratin K10 (Sigma
WH0003858M1); anti-keratins K1,10,11 (American Research
Products, Inc 03-61808), anti-involucrin (Sigma I-9018); anti-Pan
Histone (Roche 1492-519); anti-cTubulin (Sigma T-6557); anti-
UBF (Santa Cruz sc-13125); anti-Fibrillarin (Abcam ab4566).
Secondary antibodies (Jackson InmunoResearch Laboratories)
were conjugated with Texas Red, fluorescein isothiocyanate or
Cy5. Parallel control samples with no primary antibody, a negative
primary antibody anti-CD8 (Sigma C-7423); mouse IgGs (Santa
Cruz sc-2027) or rabbit antiserum, showed unspecific fluorescent
staining.
Nucleic acids were visualised with the red dye propidium
iodide (4 mg/ml final concentration) on fixed and permeabilized
cells. For detection of GFP-CTCF and GFP-BORIS fusion
proteins, transfected HEK293T cells were fixed with cold
methanol (–20uC), washed and mounted with anti-fading
mounting medium Vectashield (Vector Laboratories) with 49,69-
Diamidino-2-phenylindole dihydrochloride (DAPI) to visualize
the nucleus. Cell samples were examined and images acquired
using a Zeiss IMAGER M1 fluorescence microscope and a Zeiss
LSM 510 META confocal laser microscope equipped with argon
(488 nm) and HeNe (543 nm) and HeNe (633 nm) lasers. Z-stack
digital images were reconstructed after collecting 40 frames by a
confocal microscope (Nikon A1R) at every 0,223 mm depth and
processing by Nis elements AR, 3.2 64 bits).
Cell counting for cell cycle markers after transfection with GFP-
constructs was performed by scoring positive cells of the given
marker within the GFP positive or negative populations, taken
.1000 total cells and .100 GFP positive cells per sample from 4
different fields (micro-photographs) in duplicates.
Immunoblotting
Primary keratinocytes were lysed with a 7 M urea buffer (0.1 M
Tris-HCl pH 6.8; 7 M urea; 4% SDS; 10% 2-mercaptoethanol,
0.1% bromo phenol blue) and protein levels were determined by
immunoblot as described [22]. The membranes were incubated
with primary antibodies anti-CTCF (BD Biosciences 612148) or
anti-BORIS (Rockland 600-401-907 or abcam ab18337) and then
with fluorescent secondary antibodies (IRDye Antibodies, Li-
COR, Biosciences). The immunocomplexes were detected with an
Odyssey Infrared Imaging System (Li-COR, Biosciences). For
protein loading control, the blots were re-stained with anti-b-actin
antibody (I-19 Santa Cruz Biotech. sc-1616).
Run-on Transcription Assay and BrdU Incorporation
For immunodetection of nascent RNA, short pulses of 59-
fluorouridine (59-FU; Sigma) were performed on primary kerati-
nocytes, generally as described in [40]. Primary keratinocytes were
cultured directly on glass coverslips and 59-FU was added to a final
concentration of 2 mM in the culture medium. After 5 or 10 min,
cells were fixed with 3.7% paraformaldehyde in HPEM buffer
(30 mM Hepes, 65 mM Pipes, 2 mM EGTA, 2 mM MgCl2)
containing 0.5% Triton X-100 for 10 min The incorporation of
59-FU into nascent RNA was detected with an antibody against
halogenated UTP (anti-BrdU clone BU-33 Sigma) and a Texas
Red-conjugated secondary antibody (Jackson Laboratories).
To monitor DNA synthesis in live cells, bromodeoxyuridine
(BrdU) incorporation assays were performed. Primary keratino-
cytes growing on glass coverslips were pulsed with 40 mg/ml BrdU
(Roche) for 15 min, washed in HPEM buffer and fixed with 3.7%
paraformaldehyde as above. Cells were treated with HCl,
neutralized and sequentially incubated with anti-BrdU antibody
and Texas Red-conjugated secondary antibody. Cells were
washed and mounted with anti-fading mounting medium with
DAPI (Vector Laboratories).
Knock-down of Endogenous BORIS with shRNAs
shRNA constructs targeting BORIS were from Genecopoieia
Inc (Rockville, MD, USA; HSH003033-HIVH1). Four different
plasmids with different target sequences for BORIS (sh1,
OS245161; sh2 OS245162, sh3 OS245163 and sh 4 OS245164)
were transiently transfected into HEK293T cells using JetPEI
(Polyplus transfection). Cells were analysed 48 hours after
transfection. Quantification of mRNA transcripts was performed
using RT-PCR and all data normalized to ribosomal protein S14.
The most efficient constructs in diminishing BORIS expression
were selected (sh2 and sh4). A construct carrying a scrambled
sequence of a similar size was used as a control. All shRNAs were
associated to a GFP control to visualise transfected cells.
Flow-cytometry Analyses
Trypsinized HEK 293T cells were fixed in cold 70% ethanol
and stained with propidium iodide as described [41]. After
staining, cells were firmly resuspended and filtered through a
70 mM mesh to minimize the presence of aggregates and then
analysed on a BD FACSCantoTM. 10 000 events were gated and
acquired in list mode for every sample.
Clonogenic Growth Assay
After transfection, HEK 293T cells were placed in 6-well tissue
culture plates at a density of 104 cells/well. 14 days later, cells
were fixed and stained with Cristal violet 1% ETOH to visualize
the colonies.
Results
CTCF and BORIS Protein Expression in Normal Human
Skin
We analysed a panel of mouse tissues (15) for BORIS mRNA
expression by quantitative real time RT-PCR. These studies
identified high levels of BORIS mRNA in testis (Fig. 1A) as
previously described [11]. Lower but reproducible levels of
BORIS mRNA were also detected in other mouse tissues,
particularly in skin and at a lesser extent in spleen (Fig. 1A). We
therefore investigated BORIS mRNA expression by RT-PCR in
human skin. We found significant levels in total human skin and
freshly isolated whole dermis epidermis or disaggregated
keratinocytes (Fig. 1B and Information S1). BORIS transcripts
were detectable with the three primer sets employed, designed
to amplify different regions of BORIS mRNA (Fig. 1B and
Information S1). CTCF mRNA expression was also found in
epidermis, dermis and isolated keratinocytes (Fig. 1B). These
results suggest that BORIS is expressed in normal human skin.
In order to determine the distribution and localisation of the
two proteins in the epidermis, we investigated the expression of
CTCF and BORIS proteins by indirect immunofluorescence on
human skin sections. We labelled skin with antibodies for BORIS
or CTCF of different origins and for keratins 1 or 10 as a marker
of post-mitotic terminal differentiation. Expression of CTCF
protein was observed throughout the suprabasal layers of
epidermis with a punctate focal pattern in the whole nucleus
(Fig. 1C,E), consistent with previous reports in other cell types
[37,42,43]. In contrast, BORIS accumulated in discrete nuclear
and perinuclear spots or foci of all epidermal cells (arrows and
arrowheads, Fig. 1D,F). The distribution of CTCF and BORIS in
epidermis was confirmed with two and three different polyclonal
antibodies, respectively (see Materials and Methods), on skin
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sections from more than five different individuals. Double labelling
experiments for CTCF and BORIS by confocal or conventional
fluorescence microscopy showed the differential distribution of the
two proteins in the epidermis, whose signals did not generally co-
localise within the nucleus (Fig. 1G and Information S1). It is
important to note that the immunostaining intensity of CTCF
diminished in the more differentiated layers of the epidermis
(Fig. 1C,E and Information S1). Therefore, both proteins were
detected throughout the epidermis, although they displayed a
differential distribution.
Accumulation of BORIS in the Nucleoli and other Active
Transcription Sites
The staining pattern of BORIS in epidermal keratinocytes was
reminiscent of the nucleoli. This possibility was investigated by
staining the epidermis with propidium iodide (PI), a cytochemical
marker for nucleic acids. The nucleolus is a centre of active
synthesis and processing of rRNAs [44] and references therein)
and with the PI staining appears more intensely labelled than the
rest of the nucleus due to its high content in rRNAs (Fig. 2A). We
further performed double immunofluorescence for BORIS and
nucleolar markers UBF or Fibrillarin [45]. UBF is a transcription
factor of rRNA genes preferentially located in fibrillar centres of
the nucleolus. It plays an important role in inducing the
euchromatic state of the rDNA. Fibrillarin is involved in the
processing of pre-rRNA that takes place in the nucleolus. BORIS
strongly co-localised with both nucleolar markers within the
epidermal nuclei (Fig. 2B,C). It is to note however that while
Fibrillarin was stronger in the proliferative basal of epidermis,
nucleolar expression of BORIS was stronger in the suprabasal
layers of the epidermis, composed of differentiating cells that re-
replicate after a mitotic block (Fig. 2C; [28,32]). We also explored
the distribution of BORIS with respect to chromatin density by
double labelling with a pan-histone antibody. As shown in Fig. 2D,
BORIS localised in nuclear domains that were dull for histone
staining, corresponding to areas of low DNA density. A generally
inverse pattern was found for CTCF, predominant in bright
histone areas (not shown) and in UBF negative domains (Fig. 2E)
as previously described in other cell types [37]. Taken together,
the results from nucleolar markers and histone density suggest that
BORIS is present in less condensed DNA regions typical of
euchromatin.
We aimed to further explore the nuclear localisation of BORIS,
by expressing a GFP-fusion form of the protein. Since primary
keratinocytes are very hard to transfect, we made use of human
epithelial HEK293T cells. We performed transient transfection
with GFP-BORIS and analysed its localisation after 24 h. In cells
transfected with the control GFP vector the signal was distributed
throughout the cell (Fig. 3A). In contrast, the GFP-BORIS fusion
protein strongly localised to the nucleoli, as it was revealed by
immunostaining for BORIS, UBF or Fibrillarin (Fig. 3B–D). Both
the exogenous GFP-BORIS fusion protein and the wild-type
protein were detected with the anti-BORIS antibodies used in the
studies on skin, further confirming their specificity (Fig. 3B,E). We
assessed the overexpression of BORIS protein also by RT-PCR,
with various primer sets (Fig. 3F and Information S1) and by
western blotting, with two different polyclonal antibodies (Fig. 3G
and not shown). Interestingly, the truncated Zinc-Finger domain
of BORIS was sufficient to drive nucleolar localisation (Fig. 3H,I).
The GFP-CTCF protein showed a nucleoplasmic distribution. We
previously reported nucleolar localisation of CTCF [37]. Finally,
double transfection experiments with GFP-BORIS and Fibrillarin-
Cherry (red) showed their co-localisation in live cells (Fig. 3J and
Video S1).
We recently described an epigenetic regulation of ribosomal
chromatin by CTCF and identified two CTCF binding sites at
the intergenic region of the human rDNA repeats [39]. UBF
Figure 1. Expression of BORIS and CTCF in mouse tissues and
human skin. A) BORIS mRNA expression in mouse tissues as analysed
by quantitative RT-PCR by the comparative Ct method and normalised
to GAPDH. Data are represented as fold changes relative to the lowest
BORIS/GAPDH ratio (cartilage, designated as 1.0). For each sample,
measurements were done in duplicate using two different primer sets.
Error bars represent s.d. HEK293T cells transfected with pEGFP-mBORIS
were used as positive control (right graph). B) BORIS, CTCF and b-Actin
(internal control) mRNA expression in human skin and primary
keratinocytes by semiquantitative RT-PCR (H0.3 primer set was used,
see Information S1). Human total skin (S), dermis (D), epidermis (E) and
freshly isolated keratinocytes (K), buffer only-control (C) or molecular
weight markers (M). C,D) Indirect immunofluorescence experiments on
human skin sections with anti-CTCF or anti-BORIS antibodies as
indicated. Colours as indicated. The nuclei were visualised with DAPI
(blue). Dotted line indicates the basal membrane that separates the
epidermis (Ep) from the dermis (Der). Scale bar: 50 mm. Photographs are
representative of studies on five different human individuals with three
different polyclonal antibodies for BORIS and two different antibodies
for CTCF. E,F) Double immunofluorescence for CTCF or BORIS and
markers of post-mitotic terminal differentiation keratins K1/K10. Colours
as indicated. Scale bar: 20 mm. G) Double immunofluorescence for CTCF
(red) or BORIS (green). Scale bar: 10 mm. Arrows indicate the focal
accumulation of BORIS within the nuclei, arrowheads indicate BORIS
dots beside the nuclei. Colours as indicated.
doi:10.1371/journal.pone.0039371.g001
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was found to be a common interacting partner of CTCF and
BORIS. Consistently, chromatin immunoprecipitation assays
(CHIP) in HEK293T cells transfected with the GFP-BORIS
vector showed occupancy of rDNA sites by BORIS (Fig. 4A,B).
Therefore, both H37.9 and H42.1 rDNA sequences are
common binding sites for CTCF and BORIS at the intergenic
rDNA region.
Keratinocytes can be isolated from human skin and cultured
under conditions close to physiological [31]. We took advantage
of these primary cultures to further investigate the localisation of
Figure 2. BORIS localises to the nucleoli of human epidermal cells. A–E) Double immunofluorescence analyses were performed on human
skin sections with antibodies to BORIS or CTCF and UBF, Fibrillarin or pan-histone, as indicated. Coulors as indicated. Nucleoli were counterstained
with propidium iodie (PI) in A. Arrows point at nucleoli (A–C,E) or histone-dark areas (D). Note the coincidence between the BORIS protein, nucleolar
markers and dark-histone areas. Scale bar: 20 mm.
doi:10.1371/journal.pone.0039371.g002
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CTCF and BORIS in epidermal cells. Expression of the
endogenous proteins was first assessed in primary keratinocytes
by western blotting and immunofluorescence as above (Infor-
mation S1). The results were consistent with what observed in
the epidermis. BORIS was detected in discrete areas of the
keratinocyte nucleus (arrows; Information S1), whereas CTCF
was evenly distributed throughout the nucleus (Information S1).
To investigate the potential role of BORIS within the
keratinocyte nucleus, we performed run-on transcription assays
to detect nascent mRNA. This useful technique analyses overall
gene transcription in live cells [37,40,46]. A short pulse with 59-
fluorouridine (59FU) allows detection of foci of nascent RNA
molecules. A 10 min pulse of 59FU in keratinocytes revealed a
classical pattern of transcription foci among which the nucleolus
was the most prominent (due to transcription of ribosomal
DNA) but not the only one (arrows; Fig. 5A). Interestingly,
double staining for 59FU and endogenous BORIS revealed a
tight association not only within the nucleoli, but at all areas of
nascent RNA (Fig. 5A). On the contrary, endogenous CTCF in
keratinocytes did not localise to areas of 59FU incorporation
(Fig. 5B). Finally, we questioned whether BORIS foci were
related to DNA replication. Labelling of DNA synthesis by a
15 min pulse of BrdU incorporation showed that the distribu-
tion of endogenous BORIS or CTCF in the keratinocyte
nucleus was unrelated to DNA replication (Information S1). To
test whether there was a functional role of BORIS at sites of
transcription, we made use of specific shRNA to knock-down
the endogenous protein. Two different shRNAs against BORIS
diminished its expression with a different efficiency (Fig. 5D).
They also caused an inhibition of pre-rRNA synthesis as
assessed by RT-PCR and in situ overall transcription, as
compared with a scrambled irrelevant RNA sequence (Fig. 5D).
Figure 3. Exogenous GFP-BORIS localises to the nucleoli. A–E, H,I) Detection of GFP (green) or BORIS (red), UBF, or Fibrillarin by
immunofluorescence in HEK293T cells 24 hours after transfection with plasmids carrying GFP (A) or GFP-BORIS (B-D), wild-type BORIS (E) or GFP-Zinc
finger domain of BORIS (H,I), as indicated on the left side. The nuclei were visualised with DAPI (blue). Scale bar: 10 mm. F) Detection of BORIS mRNA
expression by RT-PCR in HEK293T cells transiently transfected as above. Primers for CTCF and b-actin were used as controls. BS: BORIS. G) Detection of
BORIS by western blotting with the antibodies used for the immunofluorescence analyses above. Note the higher molecular weight of the fusion
protein GFP-BORIS, compared to the wild-type protein (arrow). b-Actin as loading control. J) Video microphotograms showing the co-localisation of
GFP-BORIS and Fibrillarin-Cherry in live cells after transient transfection (see also Video S1).
doi:10.1371/journal.pone.0039371.g003
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Cell Cycle-dependent Centrosomal Localisation of BORIS
The localisation of BORIS in a dotty perinuclear structure in
the skin was reminiscent of centrosomes (see e.g., [28]).
Interestingly, CTCF has been reported to localise to the
centrosomes at metaphase in HeLa cells [42]. To investigate this
issue, we performed double staining for CTCF or BORIS and c-
tubulin in primary keratinocytes. Centrosomes duplicate during S
phase of the cell cycle and are key motors for the ordering and
polar separation of the chromosomal spindle during mitosis [47].
c-tubulin is a specific component of centrosomes [48]. We found
CTCF and c-tubulin co-localisation only sporadically in meta-
phase keratinocytes (Fig. 6A,C), never in interphase centrosomes
(Fig. 6D). In striking contrast, BORIS was present in the
centrosomes of all interphase keratinocytes (Fig. 6B,E), but not
in mitotic cells as the centrosomes split far apart at metaphase
(Fig. 6B,F). Detailed one-plane confocal microscopy analyses
confirmed these results in primary keratinocytes and human
epidermis (Fig. 6G,H). Centrosomal BORIS was undetectable at
the beginning of prophase and was detected again just after
cytokinesis. Similarly, BORIS centrosomal staining by confocal
analyses of epidermis was strong in interphase cells (Fig. 6H) but
was not detected in mitotic cells (not shown). Altogether, the results
suggest a dynamic localisation of CTCF and BORIS at the
centrosomes, where they alternate as the cell cycle progresses
through mitosis.
Having detected BORIS in the nucleoli and centrosomes, we
analysed its subcellular localisation in cell systems previously
reported to express the protein (Fig. 7). We found both nucleolar
and interphase-centrosomal distribution of BORIS in HeLa
(cervical cancer), HCT116 (colorectal cancer) and MCF7 (breast
cancer) cells. BORIS was also observed in the cytoplasm of these
cancer-derived cell lines, as previously reported [17,25,49]. In
contrast, CTCF was generally excluded from the nucleolus and
interphase centrosomes in these cells (Information S1). In addition,
we investigated the subcellular localisation of BORIS in mouse
normal testis, where BORIS was initially detected. We observed a
punctate distribution of BORIS in the testis epithelium as reported
(Fig. 7B; [11]). As in human epidermis, BORIS co-localised with
the nucleolar marker UBF within the nuclei (not shown) and with
the centrosomal marker c-tubulin beside the nuclei (Fig. 7B).
BORIS Induces Accumulation of Cells in S Phase and
Genomic Instability
Epidermal keratinocytes block mitosis and accumulate mitotic
cyclins as they initiate terminal differentiation [28,32]. We have
observed accumulation of BORIS in the cytoplasm of keratino-
cytes in differentiating layers of the epidermis that accumulate also
the mitotic regulator Cyclin B (Fig. 8A). To investigate whether
the accumulation of BORIS was related to a mitosis defect we
blocked freshly isolated epidermal keratinocytes at mitosis by
different inhibitors: i) Nocodazole, inhibitor of microtubule
formation (not shown), ii) BI2536 and ZM447439 (ZM77),
inhibitor of Polo-Like kinase and Aurora B kinase, respectively,
that are components of the mitosis spindle checkpoint [50]. We
also made use of hydroxyurea, that blocks cells at the beginning of
S phase. Either blocking Mitosis or S phase progression provoked
a substantial accumulation of BORIS (Fig. 8B,C, Information S1
and not shown), suggesting that the regulation of BORIS is linked
to cell cycle progression. Defects in cell cycle progression
accumulated BORIS and this was especially remarkable when
we treated primary keratinocytes with the genotoxic agent
doxorubicin (Fig. 8B,C), that induces in these cells acute DNA
damage and p53 [32].
In order to further investigate whether BORIS is involved in the
progression of S phase and mitosis, we overexpressed wild type or
GFP-BORIS by transient transfection in human epithelial
HEK293T cells as in Fig. 3 and studied the effects on the cell
cycle. As shown in Fig. 9A, overexpression of BORIS provoked an
accumulation of cells in S phase and a significant increase of large
and polyploid cells. Increased cell size is typical of mitosis failure
and re-replication [28]. These results suggest that BORIS must be
degraded in order for mitosis to progress, as other classical
regulators of S phase and mitosis (e.g., Cyclins E, A and B;
reviewed in [51]). To further explore whether the accumulation of
cells in S phase was due to an increase of proliferation or to a cell
cycle block, we performed analyses of cell cycle markers and clonal
growth. Overexpression or inactivation of BORIS caused a
decrease in the index of cell cycle markers PCNA and Cyclin A
(Fig. 9B and Information S1) and in the clonogenic cell potential to
grow (Fig. 9C). This further suggests that the regulation of BORIS
is important for the correct progression of the cell cycle, its
deregulation causing cell cycle defects.
Figure 4. Exogenous GFP-BORIS binds ribosomal DNA. A)
Scheme showing the location of the H37.9 and H42.1 sites utilised for
the studies within the ribosomal intergenic region of the rDNA repeats.
B) In vivo binding of BORIS to ribosomal DNA (rDNA). Chromatin
immunoprecipitation (ChIP) analyses with anti-BORIS (grey bars) or anti-
GFP (black bars) antibodies show BORIS occupancy of H37.9 and
H42.1 rDNA sites. Chromatin was prepared from HEK293T cells mock
transfected or transfected with GFP or GFP-BORIS expression vectors as
indicated. Relative enrichment was quantified by real-time PCR with the
H37.9 and H42.1 rDNA primer sets. Data were normalised against the
enrichment for the negative control Myc-H.1 [73]. The value for the
amount of PCR product present from ChIP assay with anti-IgG antibody
(white bars) was set as 1. Small bars are s.d. of two independent
experiments performed in duplicate samples. Bottom panels show
typical PCR products after the ChIP analyses.
doi:10.1371/journal.pone.0039371.g004
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Figure 5. Endogenous BORIS localises to nuclear active transcription sites of primary keratinocytes. A–C) Human primary keratinocytes
were pulse-labelled with 59fluorouridine (59FU) for 10 min to label nascent RNA. Double immunofluorescence was performed with an anti-BrdU
antibody to detect 59FU or Fibrillarin and anti-BORIS or anti-CTCF, as indicated. Nuclei were visualised with DAPI (blue). Colours as indicated. Note
that endogenous BORIS localises to nuclear areas of nascent RNA in the nucleolus and other small spots (arrows). Scale bar: 20 mm. D) Partial
knocking-down of BORIS by transient tranfection of scrambled (SC) or specific shRNAs in HEK293T cells affects transcription. Left bar histograms:
relative RNA expression by RT-PCR of BORIS or Pre-RNA after transfections; small bars are s.e.m. Right panels: pulse-labelled cells with 59FU after
transfections: GFP labels transfected cells, in green, 59FU in red, Dapi in blue. Note that transfections with BORIS shRNAs inhibit global transcription
(arrows), but not transfections with the scrambled control (arrows). Microphotographs representative of two independent experiments. Scale bar:
40 mm.
doi:10.1371/journal.pone.0039371.g005
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Discussion
CTCF and BORIS in Human Epidermis
We have presented a strong body of evidence for the expression
of CTCF and BORIS proteins in human epidermis. CTCF was
highly ubiquitous in the epidermis although it diminished in the
more differentiated layers. CTCF levels also decrease during
differentiation of several hematopoietic lineages [52]. CTCF has
been shown both to associate with cell growth arrest [10,21,22] or
to stimulate proliferation (in T cells; [53]). The lower level of
CTCF protein in differentiating layers of epidermis is consistent
with its function in limiting cell growth, since keratinocyte
differentiation involves cell size and cell mass increase [27,28,54].
The expression of the BORIS protein in human epidermis is
unexpected since it was initially thought to be restricted to testis.
However, Monk et al reported BORIS expression in ovary and
Figure 6. BORIS is expressed in interphase centrosomes of primary keratinocytes. A, B) Double immunofluorescence for CTCF or BORIS
(red) and centrosome marker c-tubulin (green) on primary keratinocytes, as indicated. The nuclei were visualised with DAPI (blue) Arrowheads point
at CTCF in mitotic centrosomes. Scale bar: 15 mm. C–F) High magnifications of keratinocyte nuclei showing either co-localisation (C,E) or not co-
localisation (D,F) of CTCF or BORIS with c-tubulin as indicated, in interphase (E,D) or metaphase cells (C,F). C and F are details of A and B, respectively.
Scale bar: 10 mm. G, H) Double immunofluorescence and confocal microscopy analyses of primary keratinocytes (G), or skin sections (H) showing
focal centrosomal co-localisation of BORIS (red) and c-tubulin (green). Arrowheads point at BORIS in interphase centrosomes; arrows point at BORIS in
the nucleolus of interphase cells. Scale bar: 15 mm.
doi:10.1371/journal.pone.0039371.g006
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oocytes [14]. Other cancer testis genes have been found in normal
tissues or cells other than testis [55,56] and therefore, low levels of
BORIS might be expressed in small quantities in normal tissues.
Very recently, different BORIS isoforms have been reported in
somatic cells of foetal tissues including skin [15] and BORIS
protein has been reported in the nucleolus of cultured cells from
various origins [57]. Works studying BORIS expression and
localisation have produced controversial findings [15,58,59]. This
might be due to either low sensitivity of BORIS antibodies, to the
restricted and punctate distribution of the protein in normal cells,
or both [58]. Nevertheless, the distribution of BORIS in the
epidermis that we have found was confirmed with three
independent affinity-purified polyclonal antibodies of diverse
origins (see Material and Methods). The specificity of the antibodies
Figure 7. Endogenous BORIS localises to the centrosomes in human cell lines and mouse testis. A) Double immunofluorescence analyses
were performed on the indicated human cell lines with antibodies to BORIS (green) or to c-Tubulin (red). Nuclei were visualised with DAPI (blue). Note
the distribution of BORIS in the centrosomes (arrowheads), cytoplasm (asterisks), and nucleoli (arrows). Scale bar: 40 mm. B) Single
immunofluorescence (upper panels) or double immunofluorescence (lower panels, high magnifications) as above, on sections of mouse testis.
Note a band of BORIS expression in the cyst, as described previously (upper panels, thin broken lines; Loukinov et al, 2002); thick dotted line: basal
membrane of the testis cyst. Note the co-localisation of BORIS and c-tubulin (lower panels, arrow-heads). Representative of three different biopsies
from two different specimens. L: Lumen of the cyst. Scale bar: 10 mm.
doi:10.1371/journal.pone.0039371.g007
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was also confirmed by immunofluorescence and western-blotting
on cells transfected with wild type or GFP- BORIS.
BORIS in the Nucleolus and other Transcription Sites
The nucleolus is the centre of ribosomal RNA production [60].
In the last years the nucleolus has become increasingly relevant in
the control of cellular growth and oncogenesis [61]. CTCF is a
predominantly nucleoplasmic protein with both nucleolar exclu-
sion or nucleolar localisation [37,43,62]. CTCF function might
depend on its specific localisation in the distinct nuclear
compartments. We have previously reported nucleolar localisation
of CTCF during erythroid differentiation [37] and in vivo binding
of BORIS to the nucleolar-specific factor UBF and to ribosomal
DNA [39]. In the present study we show a striking and neat
accumulation of BORIS in the nucleoli, in epidermal keratinocytes
and in a variety of human cancer cell lines where the protein had
been previously reported to be expressed. Furthermore, exogenous
GFP-BORIS accumulated in the nucleolus of human epithelial
cells. While this work was being revised, [57] reported nucleolar
localisation of BORIS in cultured cell lines and [63], reported
changes in the architecture of the nucleolus in the absence of
CTCF. BORIS and CTCF exhibit high homology in the central
11 Zinc-Finger domain. We have shown that this domain is
responsible for nucleolar targeting of both CTCF [37] and BORIS
(herein). Interestingly, the nucleolar transcription factor UBF is the
only common interacting partner of CTCF and BORIS so far
identified [39]. However, we did not clearly find endogenous
CTCF within the nucleolus in our studies. Likely, the translocation
of CTCF from the nucleoplasm to the nucleolus is a dynamic
process, consequence of functional interactions with other
macromolecules through the N- and C- terminus domains.
A similar transit at the nucleolus has been reported for other
nuclear factors [64]. For instance the transcription factor MYC is
rarely found in the nucleoli yet it plays an important role in the
regulation of rDNA transcription. In addition, we have previously
shown that CTCF goes to the nucleoli during erythroid differenti-
ation, which involves cell growth arrest [37]. Within the epidermis,
nucleolar CTCF might be present in individual cells at a very
particular time and be hardly detectable. This would be in agreement
with its reported function in cell growth arrest, since epidermal cells
are continuously undergoing cellular growth [28,32].
In our experiments, BORIS not only localised to the nucleolus
within the nucleus. It was frequently detected in other nuclear
spots in human keratinocytes both in the epidermis and in primary
cultures. Labelling nascent RNA in live cells showed that the
endogenous protein was present in sites of RNA transcription.
Moreover, knocking-down BORIS with specific shRNAs caused a
reduction in the synthesis of rRNA (RT-PCR) and global RNA (in
vivo labelling). This suggests a role for BORIS in the licensing of
RNA transcription.
BORIS in the Centrosome
BORIS localised in the centrosomes in the epidermis of skin
section and in primary keratinocytes, as revealed by co-localisation
with the specific centrosome-specific marker c-tubulin. We also
found BORIS in the centrosomes of mouse testis and a variety of
human non-tumour or cancer cell lines of different origins. BORIS
was present in the centrosomes up to prometaphase, when they split
Figure 8. Accumulation of BORIS upon S phase and mitosis arrest. A) BORIS accumulates in differentiating keratinocytes of epidermis
undergoing mitosis arrest as revealed by double labelling of human epidermis for BORIS (red) and Cyclin B (green); nuclear DNA (DAPI, blue). Scale
bar: 15 mm. B) BORIS accumulates in primary keratinocytes treated for 24 h with inhibitors of the G1/S transition of the cell cycle (hydroxyurea, HU),
the mitosis checkpoint (ZM77 for Aurora B kinase), or the genotoxic agent doxorubicin (DOXO). Microphotographs show merge of anti-BORIS, anti-c-
tubulin for centrosomes (green) and DAPI for nuclear DNA (blue). Scale bar: 10 mm. Arrows point at accumulation of BORIS. Note that DOXO provokes
a generalised increased of BORIS. C) Relative BORIS mRNA as measured by RT-PCR, in primary keratinocytes treated as above. Representative of three
independent experiments with cells from two different human individuals.
doi:10.1371/journal.pone.0039371.g008
Cell Cycle Role of BORIS
PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e39371
far apart and then it became undetectable (Fig. 10). Centrosomes
duplicate during S phase and split apart at the beginning of mitosis
[65]. Through the control of microtubule nucleation, they are
involved in the assembly and organization of the mitotic bipolar
spindle that ensures accurate chromosome segregation. The
subcellular distribution of BORIS in both nucleoli and centrosomes
might seem intriguing. However, proteins with a similar dual
distribution have been described previously and might have a role in
coordinating S phase with mitosis [66,67]. For instance, they can
inhibit centrosome duplication until the S phase is completed. One
of these proteins is nucleophosmin/B23, which is involved in
ribosome biogenesis and localises to the centrosome to prevent it
from duplication (Fig. 10). They might thus contribute to maintain
genome integrity.
Interestingly, CTCF has been reported to localise to metaphase
centrosomes [42,43] and to interact with nucleophosmin/B23
[68]. Therefore both CTCF and B23 are detected in centrosomes
from metaphase to G1 phase, precisely when BORIS is not there
detectable. This alternate pattern of CTCF and BORIS associ-
ation with the centrosomes may be important for their function
during the cell cycle (Fig. 10).
Potential Functions of BORIS
Despite BORIS being expressed in a variety of human
malignancies, little is known about its biological functions. This
issue has in part been hampered by the fact that detection of
BORIS was initially restricted to testis [11]. The detection of
BORIS in normal epidermis provides new insight.
BORIS and CTCF are thought to have opposed functions
[10,11]. Although they have a highly conserved DNA binding
domain and thus they are thought to bind to the same sites, they
are often expressed in a different manner. CTCF is ubiquitous in
normal tissues, has cell growth restrictive activities and is often lost
in cancer [20]. In contrast, BORIS is detected in cancer and in
immortalised cell lines, suggesting that it associates with cell
growth [10,11]. This may explain why tissues with a high cell turn-
over (such as testis and epidermis) express more detectable levels of
BORIS. Interestingly, within the epidermal nuclei CTCF accu-
mulated mainly around regions of heterochromatin whereas
BORIS localised to areas of euchromatin, on basis of the DNA
and histone density. Euchromatin is formed by decondensed
chromatin required to allow DNA replication or transcription.
Considering the presence of BORIS in euchromatin domains,
the evidence involving the endogenous protein in global
transcription and the role of CTCF in chromatin remodelling, it
is tempting to speculate that BORIS might participate in the
unfolding of the chromatin preceding transcription. This would
explain why BORIS is undetectable during mitosis, when
chromatin is highly condensed. Within the same lines, when we
partially inhibited the endogenous BORIS protein by shRNAs,
RNA transcription was significantly inhibited. This model is
consistent with the frequent overexpression of BORIS in cancer
cells [60]. It is unclear what drives the two proteins to different
sites according to the different needs. Some studies have found an
association between CTCF and BORIS DNA binding and the
chromatin status (reviewed in [69]). It is conceivable that DNA
methylation, specific histone modifications and different binding
partners may influence the binding of CTCF or BORIS to the
Figure 9. Involvement of BORIS in cell cycle progression and genomic instability. A) Ectopic expression of BORIS causes cell accumulation
in S phase, polyploidy and cell size increase. Human embryo epithelial HEK293T cells were transfected with GFP-BORIS, the wild type gene (WT-BORIS)
or no DNA (control). Bar histogram shows the quantitations of flow-cytometry analyses of two independent experiments 60 h after transient
transfections. Small bars are s.d.m. The gates used for the quantitations are shown below in representative flow-cytometry histograms for the cell
cycle (DNA content, in red) or cell size (Forward Scatter, in blue), 48 h or 60 h after transient transfections with the indicated genes. B) Transient
transfection (48 h) with GFP-BORIS or scrambled control shRNA (GFP-SC) or BORIS-specific shRNAs (GFP- sh2, sh4) reduces the index of HEK293T cells
expressing cell cycle markers PCNA or Cyclin A; small bars are the s.e.m. of duplicate samples. C) Clonogenic growth potential of HEK293T cells 7 days
after transfections as above; note the decreased colony forming efficiency after transfection with GFP-BORIS or BORIS sh2.
doi:10.1371/journal.pone.0039371.g009
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chromatin [39] and this is an issue to pursue. Within the same
lines, the state of DNA methylation and histone modifications has
been found to change during epidermal differentiation [29].
Overexpression of BORIS caused an accumulation of cells in S
and G2/M phases of the cell cycle. This effect was unrelated to an
increase of the cell cycle and proliferation. First, there was no
apparent association between endogenous BORIS and sites of
DNA replication. Second, the proportion of cells expressing cell
cycle markers PCNA or Cyclin A diminished after transfection
with BORIS, as well as the capacity to grow and form colonies.
The accumulation of cells in S phase and mitosis upon
overexpression of BORIS might be consequence of replication
defects induced by altered chromatin unfolding and/or defects in
coordinating S phase with mitosis. During the cell cycle, mitosis
must not start before the S phase is completed and S phase
regulators are degraded [51]. BORIS might thus have a role in
coordinating S phase with mitosis and when deregulated, in
genomic instability. Consistently, in our experiments ectopic
expression of BORIS caused polyploidy, a marker of mitotic
failure and genomic instability. Moreover, the inhibition of
endogenous BORIS by shRNAs caused a decrease in the cell
cycle index and in the clonogenic capacity. Other lines of evidence
further support a role of BORIS in genome instability:
i) in our experiments, BORIS accumulated in the cytoplasm
of keratinocytes upon a mitosis block caused by differen-
tiation or by inhibitors of Aurora B and Polo-like kinase,
members of the spindle checkpoint [65];
ii) the most striking accumulation of BORIS in keratinocytes
occurred in response to doxorubicin, that causes DNA
damage, and proteins involved in the DNA damage
checkpoint have been found in the centrosome [70].
iii) within the epidermis, BORIS accumulated with mitotic
Cyclin B in the cytoplasm of suprabasal cells arrested in
mitosis;
iv) BORIS accumulates in the cytoplasm of pre-meiotic
spermatocytes and when absent in mice it provokes defects
in spermatogenesis [11,16].
v) CTCF has been shown to interact with cohesins [71],
proteins that hold sister chromatids together during
metaphase. Interestingly, cohesins have recently been found
in the centrosomes, to keep them together until they
separate before mitosis [72].
vi) inactivation of CTCF and the guardian of the genome p53,
provokes strong activation of BORIS [25].
In summary, optimal levels of BORIS may be needed to
support normal cell division. Conversely, defects in cell division
may lead to the accumulation of cytoplasmic non-functional
BORIS. CTCF and BORIS might thus antagonise each other as
the different needs for chromatin folding or unfolding and
centrosome duplication and separation succeed during the cell
cycle (Fig. 10). They also might have a role in linking these events
with centrosome duplication and mitosis. This model is consistent
with the proposed activity of CTCF as a tumour suppressor and
the frequent deregulation of BORIS in cancer.
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